

Contents

1. Description
 - 1.1 Background information
 - 1.2 Applications
2. Recommendations for *in vitro* restimulation of antigen-specific T cells with PepTivator Peptide Pools
 - 2.1 Cell preparation
 - 2.2 Reagent requirements
 - 2.3 Recommendation for *in vitro* restimulation of antigen-specific T cells
3. Examples
 - 3.1 Detection of CMV pp65-specific T cells by intracellular staining with IFN- γ Antibody, anti-human, PE
 - 3.2 IFN- γ production upon stimulation with peptide pools
4. References

1. Description

This product is for research use only.

Components	1×96-well plate, consisting of 12 strips of 8 wells Pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids (aa) overlap, covering the complete sequence of the pp65 protein of human cytomegalovirus (CMV) strain AD169 (Swiss-Prot Acc. no. P06725).
Capacity	96 wells containing 0.06 nmol (0.1 μ g) per peptide per well. One well is for stimulation of up to 10^6 total cells.
Product format	Lyophilized peptides containing stabilizer.
Purity	Each peptide >80% (HPLC), low endotoxin.
Storage	Store lyophilized product at -20°C . Protect from humidity. The expiration date is indicated on the product label.

This product contains no preservatives; always handle under aseptic conditions.

1.1 Background information

The PepTivator – HT Peptide Pools are designed for the simple stimulation of antigen-specific T cells. The convenient 96-well format, composed of 12 individually removable strips of 8 wells each allows for easy and flexible experimental set-up. Thus different antigens can be combined in one plate.

CMV is a member of the herpesvirus group and belongs to the subfamily of beta-herpesviruses. Between 50–85% of human adults are infected with CMV. Once infected, the virus persists in the organism. The infection is asymptomatic in healthy individuals, but in immunocompromised patients CMV can cause severe diseases.

CMV pp65 (65 kDa lower matrix phosphoprotein)¹, also known as glycoprotein 64 or UL83, is a virion tegument protein and the main component of the enveloped subviral particle. CMV pp65 is an immunodominant target of CD4⁺ as well as CD8⁺ T cell responses to CMV.² CMV pp65-specific T cells predominantly produce inflammatory cytokines like IFN- γ , IL-2, and TNF- α .

The PepTivator Peptide Pools have been specially developed for efficient *in vitro* stimulation of antigen-specific CD4⁺ and CD8⁺ T cells, as peptides of 15 amino acid length with 11 amino acid overlap represent the optimized solution for stimulating both CD4⁺ and CD8⁺ T cells in various applications. Stimulation of T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and upregulation of activation markers, which then allows the detection or isolation of antigen-specific T cells. Quantitative, phenotypical, or functional analysis of antigen-specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.

1.2 Applications

- Detection and analysis of antigen-specific CD4⁺ and CD8⁺ effector/memory T cells, for example, in peripheral blood mononuclear cells (PBMCs), by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
- Immunomonitoring of various antigen specificities in one plate.
- Generation of antigen-specific CD4⁺ and CD8⁺ effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination.
- Pulsing of antigen-presenting cells for research on dendritic cell vaccination.

2. Recommendations for *in vitro* restimulation of antigen-specific T cells with PepTivator Peptide Pools

2.1 Cell preparation

For induction of cytokine secretion by antigen-specific T cells, best results are achieved by stimulation of fresh PBMCs, whole blood, or other leukocyte-containing single-cell preparations from tissues or cell lines. Alternatively, frozen cell preparations can be used.

▲ **Note:** Remove platelets after density gradient separation. Resuspend cell pellet, fill tube with buffer, and mix. Centrifuge at 200×g for 10–15 minutes at 20 °C. Carefully remove supernatant.

▲ **Note:** PBMCs may be stored overnight. The cells should be resuspended and incubated in culture medium as described in 2.4, steps 1–3, but without addition of antigen. The antigen is then added to the culture on the next day.

For details about cell preparation refer to the protocols section at www.miltenyibiotec.com/protocols.

2.2 Reagent requirements

- Culture medium, e.g., TexMACS™ Medium (# 130-097-196) or RPMI 1640 containing 5% human serum, e.g., autologous or AB serum.
▲ **Note:** Do not use bovine serum albumin (BSA) or fetal bovine serum (FBS) because of non-specific stimulation.
- Control plate (8×12) (# 130-098-235).
- (Optional) Further PepTivator – HT Peptide Pools, e.g., PepTivator AdV5 Hexon – HT (# 130-098-237).
- (Optional) Kits for the isolation and/or detection of cytokine-secreting T cells, e.g., IFN-γ Secretion Assay – Cell Enrichment and Detection Kit (PE), human (# 130-054-201) or TNF-α Secretion Assay – Cell Enrichment and Detection Kit (PE), human (# 130-091-269).
- (Optional) Antibodies or kits for intracellular cytokine staining, e.g., IFN-γ Antibody, anti-human, PE. For more information about antibodies refer to www.miltenyibiotec.com/antibodies.
- (Optional) Cell surface staining of CD154 by using CD154 antibodies, human and CD40 pure – functional grade, human (# 130-094-133).
- (Optional) CytoStim™ (# 130-092-172, # 130-092-173) for restimulation of human T cells.
- (Optional) PepTivator CEF MHC Class I Plus – premium grade (# 130-098-426) as a peptide-specific positive control.

2.3 Recommendations for *in vitro* restimulation of antigen-specific T cells

▲ Before removing the plate from the aluminium pouch, warm up to room temperature. Remove the necessary amount of strips. Store the remaining ones at –20 °C in the tightly sealed aluminium pouch protected from humidity.

▲ CMV pp65-specific T cells are expected to be present only in certain individuals. Their frequency may be low compared to T cells with other specificities. The given protocol for *in vitro* T cell stimulation thus may only serve as a guideline.

▲ Always include a negative control (without antigen) in the experiment. As a positive control, a sample stimulated with, e.g., PepTivator CEF MHC Class I Plus or CytoStim may also be

included.

1. Wash cells by adding medium, centrifuge at 300×g for 10 minutes. Aspirate supernatant.
2. Resuspend cells in culture medium at 10⁷ cells per mL. Add 100 µL of the cell suspension to each well (10⁶ cells/well). The final concentration of PepTivator CMV pp65 – HT in the cell suspension is 0.6 nmol of each peptide/mL.
3. Incubate cells at 37 °C and 5% CO₂.

Cytokine Secretion Assay: Incubate cells for 3–6 hours.

Cell surface staining of CD154: Add CD40 antibody pure – functional grade to the cell culture.

Intracellular cytokine staining with antibodies or kits: Incubate cells for 2 hours, then add 1 µg/mL brefeldin A, and incubate for further 4 hours.

4. Collect cells carefully by using a cell scraper, or by pipetting up and down when working with smaller volumes. Rinse the dish with cold buffer. Check microscopically for any remaining cells, if necessary, rinse the dish again.


To proceed with the Cytokine Secretion Assay or intracellular cytokine staining, please refer to the respective data sheet.

▲ **Note:** When preparing cells for intracellular cytokine staining, fixed cells may be stored at 2–8 °C for up to 1 week.

3. Examples


3.1 Detection of CMV pp65-specific T cells by intracellular staining with IFN-γ Antibody, anti-human, PE

From a CMV⁺ donor 10⁶ human PBMCs were restimulated for 6 hours with PepTivator CMV pp65 or without antigen. After 2 hours 1 µg/mL Brefeldin A was added. Cells were fixed, permeabilized, and CMV pp65-specific cells were intracellularly stained with Anti-IFN-γ-PE. T cells were counterstained for CD4 and CD8 expression. IFN-γ production of T cells is shown.



3.2 IFN- γ production upon stimulation with peptide pools

The following figure shows the production of IFN- γ by human CD4⁺ or CD8⁺ T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).



4. References

- Pande, H. *et al.* (1984) Cloning and physical mapping of a gene fragment coding for a 64- kilodalton major late antigen of human cytomegalovirus. *Proc. Natl. Acad. Sci. USA.* 81: 4965–4969.
- Kern, F. *et al.* (2002) Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. *J. Infect. Dis.* 185: 1709–1716.

Refer to www.miltenyibiotec.com for all data sheets and protocols. Miltenyi Biotec provides technical support worldwide. Visit www.miltenyibiotec.com for local Miltenyi Biotec Technical Support contact information.

Legal notices

Limited product warranty

Miltenyi Biotec B.V. & Co. KG and/or its affiliate(s) warrant this product to be free from material defects in workmanship and materials and to conform substantially with Miltenyi Biotec's published specifications for the product at the time of order, under normal use and conditions in accordance with its applicable documentation, for a period beginning on the date of delivery of the product by Miltenyi Biotec or its authorized distributor and ending on the expiration date of the product's applicable shelf life stated on the product label, packaging or documentation (as applicable) or, in the absence thereof, ONE (1) YEAR from date of delivery ("Product Warranty"). Miltenyi Biotec's Product Warranty is provided subject to the warranty terms as set forth in Miltenyi Biotec's General Terms and Conditions for the Sale of Products and Services available on Miltenyi Biotec's website at www.miltenyibiotec.com, as in effect at the time of order ("Product Warranty"). Additional terms may apply. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF A PRODUCT IS SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION METHODS.

Technical information

The technical information, data, protocols, and other statements provided by Miltenyi Biotec in this document are based on information, tests, or experience which Miltenyi Biotec believes to be reliable, but the accuracy or completeness of such information is not guaranteed. Such technical information and data are intended for persons with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. Miltenyi Biotec shall not be liable for any technical or editorial errors or omissions contained herein.

All information and specifications are subject to change without prior notice. Please contact Miltenyi Biotec Technical Support or visit www.miltenyibiotec.com for the most up-to-date information on Miltenyi Biotec products.

Licenses

This product and/or its use may be covered by one or more pending or issued patents and/or may have certain limitations. Certain uses may be excluded by separate terms and conditions. Please contact your local Miltenyi Biotec representative or visit Miltenyi Biotec's website at www.miltenyibiotec.com for more information.

The purchase of this product conveys to the customer the non-transferable right to use the purchased amount of the product in research conducted by the customer (whether the customer is an academic or for-profit entity). This product may not be further sold. Additional terms and conditions (including the terms of a Limited Use Label License) may apply.

CUSTOMER'S USE OF THIS PRODUCT MAY REQUIRE ADDITIONAL LICENSES DEPENDING ON THE SPECIFIC APPLICATION. THE CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING FOR ITSELF WHETHER IT HAS ALL APPROPRIATE LICENSES IN PLACE. Miltenyi Biotec provides no warranty that customer's use of this product does not and will not infringe intellectual property rights owned by a third party. BY USE OF THIS PRODUCT, THE CUSTOMER AGREES TO BE BOUND BY THESE TERMS.

Trademarks

CytoStim, MACS, the Miltenyi Biotec logo, PepTivator, and TexMACS are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. All other trademarks mentioned in this publication are the property of their respective owners and are used for identification purposes only.

Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.